Mayne Pharma Group's ROE % for the quarter that ended in Dec. 2025 was -8.27%. Mayne Pharma Group's PB Ratio for the quarter that ended in Dec. 2025 was 0.72.
Mayne Pharma Group's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -11.49%.
Mayne Pharma Group ROE % Adjusted to Book Value Related Terms
Mayne Pharma Group ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Mayne Pharma Group's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayne Pharma Group ROE % Adjusted to Book Value Chart
ASX:MYX vs MCK, CAH, COR: ROE % Adjusted to Book Value Comparison
For the Medical Distribution subindustry, Mayne Pharma Group's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayne Pharma Group ROE % Adjusted to Book Value vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Mayne Pharma Group's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -11.49% mean?
Mayne Pharma Group (ASX:MYX) has a ROE % Adjusted to Book Value of -11.49% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Mayne Pharma Group and its competitors.
Is Mayne Pharma Group's ROE % Adjusted to Book Value too high?
Mayne Pharma Group's current ROE % Adjusted to Book Value is -11.49%. Overall, Mayne Pharma Group has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's ROE % Adjusted to Book Value compare to MCK and CAH?
Mayne Pharma Group's ROE % Adjusted to Book Value of -11.49% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Distribution company?
A good ROE % Adjusted to Book Value depends on the Medical Distribution industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Mayne Pharma Group and its competitors. Mayne Pharma Group's current ROE % Adjusted to Book Value is -11.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (ASX:MYX) is currently considered Possible Value Trap. The stock's GF Value™ is A$5.31, compared to a current price of A$2.67 — trading 49.7% below its estimated fair value. The current ROE % Adjusted to Book Value is -11.49%. Mayne Pharma Group's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Mayne Pharma Group (ASX:MYX), the current ROE % Adjusted to Book Value is -11.49% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayne Pharma Group (ASX:MYX) Overvalued in 2026?
Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued.
The current stock price of A$2.67 is trading 49.7% below its estimated GF Value™ of A$5.31.
GuruFocus considers Mayne Pharma Group to be Possible Value Trap.
Key valuation signals for ASX:MYX:
ROE % Adjusted to Book Value: -11.49%
GF Value™: A$5.31 vs. price of A$2.67 (49.7% below fair value)
No single metric tells the full story. See the ASX:MYX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
51GF Score
Get the complete analysis for ASX:MYX
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MYX has been successfully added to your 
